Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,066,561
  • Shares Outstanding, K 80,288
  • Annual Sales, $ 806,780 K
  • Annual Income, $ -363,300 K
  • EBIT $ 953 M
  • EBITDA $ 1,177 M
  • 60-Month Beta 0.49
  • Price/Sales 3.62
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 41.26% (+4.81%)
  • Historical Volatility 31.09%
  • IV Percentile 3%
  • IV Rank 5.21%
  • IV High 128.79% on 04/24/25
  • IV Low 36.45% on 01/21/26
  • Expected Move (DTE 29) 8.75 (11.48%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 23
  • Volume Avg (30-Day) 149
  • Put/Call OI Ratio 0.81
  • Today's Open Interest 4,315
  • Open Int (30-Day) 5,769
  • Expected Range 67.42 to 84.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 7
  • High Estimate 2.39
  • Low Estimate -1.41
  • Prior Year -0.24
  • Growth Rate Est. (year over year) -54.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
69.81 +9.11%
on 01/20/26
80.18 -5.00%
on 01/13/26
-2.73 (-3.46%)
since 12/22/25
3-Month
65.81 +15.74%
on 10/24/25
87.50 -12.95%
on 11/26/25
+9.65 (+14.51%)
since 10/22/25
52-Week
35.95 +111.88%
on 05/06/25
87.50 -12.95%
on 11/26/25
+31.09 (+68.97%)
since 01/22/25

Most Recent Stories

More News
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –

PTCT : 76.17 (+0.81%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing...

PTCT : 76.17 (+0.81%)
PTC Therapeutics Announces Approval of Sephienceâ„¢ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan

– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC –

PTCT : 76.17 (+0.81%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , Dec. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate...

PTCT : 76.17 (+0.81%)
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

WARREN, N.J. , Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44 th Annual J.P. Morgan Healthcare Conference...

PTCT : 76.17 (+0.81%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , Dec. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate...

PTCT : 76.17 (+0.81%)
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation...

PTCT : 76.17 (+0.81%)
CVKD : 7.64 (+7.45%)
Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

NEW YORK , Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: 

PTCT : 76.17 (+0.81%)
IPG : 24.57 (-1.96%)
SNDK : 503.44 (+0.43%)
OMC : 79.24 (+0.84%)
UPWK : 21.13 (+7.31%)
SPGI : 539.80 (+1.63%)
PINC : 28.26 (+0.32%)
GIL : 67.05 (+1.15%)
FIBK : 38.22 (+0.45%)
HBI : 6.47 (-1.82%)
GIL.TO : 92.48 (+0.87%)
PTC Therapeutics to Host R&D Day

Event to take place on Dec. 2, 2025 in New York City

PTCT : 76.17 (+0.81%)
PTC Therapeutics: Q3 Earnings Snapshot

PTC Therapeutics: Q3 Earnings Snapshot

PTCT : 76.17 (+0.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 80.64
2nd Resistance Point 79.00
1st Resistance Point 77.58
Last Price 76.17
1st Support Level 74.52
2nd Support Level 72.88
3rd Support Level 71.46

See More

52-Week High 87.50
Last Price 76.17
Fibonacci 61.8% 67.81
Fibonacci 50% 61.72
Fibonacci 38.2% 55.64
52-Week Low 35.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar